Long non-coding RNAs(lncRNAs)are a novel class of non-coding RNA(ncRNA),that have been studied extensively in the field of tumor research in recent years.In the case of tumor-associated lncRNAs,lncRNA cytoskeleton reg...Long non-coding RNAs(lncRNAs)are a novel class of non-coding RNA(ncRNA),that have been studied extensively in the field of tumor research in recent years.In the case of tumor-associated lncRNAs,lncRNA cytoskeleton regulator RNA(CYTOR)displays extensive functions in tumorigenesis,including invasion,metastasis,malignant proliferation,glycolysis,and inflammatory response.Moreover,the dysregulation of CYTOR is closely related to clinicopathological characteristics,such as tumor stage,lymph node metastasis and infiltration,and poor prognosis of tumor patients.In this review,we provide a novel strategy to summarize the biological functions and clinical value of CYTOR in tumors through an overview of the literature combined with gene set enrichment analysis.A deeper understanding of the role of CYTOR in tumorigenesis may provide new diagnostic,prognostic and therapeutic markers for human tumors.展开更多
Malignant peritoneal mesothelioma(PM) is an infrequent disease which has historically been associated with a poor prognosis. Given its long latency period and non-specific symptomatology, a diagnosis of PM can be sugg...Malignant peritoneal mesothelioma(PM) is an infrequent disease which has historically been associated with a poor prognosis. Given its long latency period and non-specific symptomatology, a diagnosis of PM can be suggested by occupational exposure history, but ultimately relies heavily on imaging and diagnostic biopsy. Early treatment options including palliative operative debulking, intraperitoneal chemotherapy, and systemic chemotherapy have marginally improved the natural course of the disease with median survival being approximately one year. The advent of cytoreduction(CRS) with hyperthermic intraperitoneal chemotherapy(HIPEC) has dramatically improved survival outcomes with wide median survival estimates between 2.5 to 9 years; these studies however remain largely heterogeneous, with differing study populations, tumor biology, and specific treatment regimens. More recent investigations have explored extent of cytoreduction, repeated operative intervention, and choice of chemotherapy but have been unable to offer definitive conclusions. CRS and HIPEC remain morbid procedures with complication rates ranging between 30% to 46% in larger series. Ac-cordingly, an increasing interest in identifying molecular targets and developing targeted therapies is emerging. Among such novel targets is sphingosine kinase 1(SphK1) which regulates the production of sphingosine-1-phosphate, a biologically active lipid implicated in various cancers including malignant mesothelioma. The known action of specific SphK inhibitors may warrant further exploration in peritoneal disease.展开更多
基金supported by the National Natural Science Foundation of China(No.81974424,81874133,81772903 and 81903032)Natural Science Foundation of Hunan Province,China(No.2018JJ2630 and 2021JJ41013)+2 种基金the Huxiang Young Talent Project,China(No.2018RS3024)the China Postdoctoral Science Foundation(No.2020M672520)the Youth Fund of Xiangya Hospital,China(No.2018Q011).
文摘Long non-coding RNAs(lncRNAs)are a novel class of non-coding RNA(ncRNA),that have been studied extensively in the field of tumor research in recent years.In the case of tumor-associated lncRNAs,lncRNA cytoskeleton regulator RNA(CYTOR)displays extensive functions in tumorigenesis,including invasion,metastasis,malignant proliferation,glycolysis,and inflammatory response.Moreover,the dysregulation of CYTOR is closely related to clinicopathological characteristics,such as tumor stage,lymph node metastasis and infiltration,and poor prognosis of tumor patients.In this review,we provide a novel strategy to summarize the biological functions and clinical value of CYTOR in tumors through an overview of the literature combined with gene set enrichment analysis.A deeper understanding of the role of CYTOR in tumorigenesis may provide new diagnostic,prognostic and therapeutic markers for human tumors.
基金Supported by United States National Institute of Health(to Kazuaki Takabe),No.R01CA160688Investigator Initiated Research Grant(to Susan G Komen),No.IIR12222224
文摘Malignant peritoneal mesothelioma(PM) is an infrequent disease which has historically been associated with a poor prognosis. Given its long latency period and non-specific symptomatology, a diagnosis of PM can be suggested by occupational exposure history, but ultimately relies heavily on imaging and diagnostic biopsy. Early treatment options including palliative operative debulking, intraperitoneal chemotherapy, and systemic chemotherapy have marginally improved the natural course of the disease with median survival being approximately one year. The advent of cytoreduction(CRS) with hyperthermic intraperitoneal chemotherapy(HIPEC) has dramatically improved survival outcomes with wide median survival estimates between 2.5 to 9 years; these studies however remain largely heterogeneous, with differing study populations, tumor biology, and specific treatment regimens. More recent investigations have explored extent of cytoreduction, repeated operative intervention, and choice of chemotherapy but have been unable to offer definitive conclusions. CRS and HIPEC remain morbid procedures with complication rates ranging between 30% to 46% in larger series. Ac-cordingly, an increasing interest in identifying molecular targets and developing targeted therapies is emerging. Among such novel targets is sphingosine kinase 1(SphK1) which regulates the production of sphingosine-1-phosphate, a biologically active lipid implicated in various cancers including malignant mesothelioma. The known action of specific SphK inhibitors may warrant further exploration in peritoneal disease.
